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ORIGINAL ARTICLE
Generation of Functional Human Adipose Tissue
in Mice from Primed Progenitor Cells
Raziel Rojas-Rodriguez,1,* Jorge Lujan-Hernandez, MD,2,* So Yun Min, PhD,1,* Tiffany DeSouza,1,*
Patrick Teebagy,2 Anand Desai, MS,1 Heather Tessier,2 Robert Slamin,2 Leah Siegel-Reamer,2 Cara Berg,1
Angel Baez,2 Janice Lalikos, MD,2,{ and Silvia Corvera, MD1,{
Adipose tissue (AT) is used extensively in reconstructive and regenerative therapies, but transplanted fat
often undergoes cell death, leading to inflammation, calcification, and requirement for further revision surgery.
Previously, we have found that mesenchymal progenitor cells within human AT can proliferate in three-
dimensional culture under proangiogenic conditions. These cells (primed ADipose progenitor cells, PADS)
robustly differentiate into adipocytes in vitro (ad-PADS). The goal of this study is to determine whether ad-
PADS can form structured AT in vivo, with potential for use in surgical applications. Grafts formed from ad-
PADS were compared to grafts formed from AT obtained by liposuction after implantation into nude mice.
Graft volume was measured by microcomputed tomography scanning, and the functionality of cells within the
graft was assessed by quantifying circulating human adiponectin. The degree of graft vascularization by donor
or host vessels and the content of human or mouse adipocytes within the graft were measured using species-
specific endothelial and adipocyte-specific quantitative real time polymerase chain reaction probes, and his-
tochemistry with mouse and human-specific lectins. Our results show that ad-PADS grafted subcutaneously into
nude mice induce robust vascularization from the host, continue to increase in volume over time, express the
human adipocyte marker PLIN1 at levels comparable to human AT, and secrete increasing amounts of human
adiponectin into the mouse circulation. In contrast, grafts composed of AT fragments obtained by liposuction
become less vascularized, develop regions of calcification and decreased content of PLIN1, and secrete lower
amounts of adiponectin per unit volume. Enrichment of liposuction tissue with ad-PADS improves vascular-
ization, indicating that ad-PADS may be proangiogenic. Mechanistically, ad-PADS express an extracellular
matrix gene signature that includes elements previously associated with small vessel development (COL4A1).
Thus, through the formation of a proangiogenic environment, ad-PADS can form functional AT with capacity
for long-term survival, and can potentially be used to improve outcomes in reconstructive and regenerative
medicine.
Keywords: mice, nude, regenerative medicine, adipocytes, adipose tissue, adipogenesis, stem cells, extracel-
lular matrix
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Introduction
Adipose tissue (AT) is uniquely capable of great ex-pansion as a function of chronic excess nutrient con-
sumption. Indeed, AT can expand to comprise up to 70% of
human body mass.1 The capacity of AT to grow and pro-
mote angiogenesis has fueled the use of fat grafting in
numerous medical contexts.2–6 For example, AT is used
for volume restoration after surgery for breast cancer,7
for soft tissue reconstruction in acquired or congenital
malformations,8,9 and to fill defects such as cranial fractures
or fistulas in cranial neurosurgery.10–12 In the context of
regeneration, mesenchymal cells from AT have been used
for numerous purposes, including cardiomyocyte,13 bowel,14
tendon, and bone regeneration.15 In the setting of volume
restoration, reabsorption and necrosis of grafted fat are a
frequent complication,16,17 resulting in the need for repeated
surgical procedures in >25% of cases. While empirical meth-
ods to improve fat grafting outcomes have been identified,18
a further understanding of the cellular and molecular mech-
anisms of adult human AT development is required to fully
leverage its therapeutic potential.
Human adult AT is enriched in mesenchymal stem cells
(known as ADipose stem cells, ADSCs), which are capable
of differentiation toward the adipogenic, myogenic, chon-
drogenic, and osteogenic lineages.19–21 ADSCs were iden-
tified and are routinely obtained from the stromovascular
fraction (SVF) of AT and may underlie the capacity of AT
to expand, thus playing an important role in the outcome of
fat grafting. Indeed, in some studies, supplementation of AT
with cells from the SVF, which contains ADSCs, displayed
significant improvements in volume retention after graft-
ing,22 and controlled clinical trials support a specific role for
ADSCs in graft improvement.23 The mechanisms by which
ADSCs improve grafting are unclear, but they could function
by providing new adipocytes or their vascular support.24,25 A
limitation of the use of ADSCs is that relatively few cells can
be obtained by conventional enzymatic digestion, and they
display loss of differentiation potential with passaging.26,27
Thus, the therapeutic use of ADSCs is restricted to instances
in which relatively large amounts of AT can be collected.
A potential alternative approach to obtaining AT progen-
itor cells is to leverage the mechanisms by which AT expands
physiologically. Previous studies indicate that development
of AT is preceded by the formation of a vascular plexus, and
lineage-tracing studies have shown that adipocyte progenitors
are localized within the adult AT vasculature.28–36 These
findings suggested the possibility that vascular expansion
would be accompanied by adipocyte progenitor proliferation.
We tested this hypothesis by culturing human AT explants
under proangiogenic conditions that elicited capillary sprout
formation, and found concomitant robust proliferation of
adipocyte progenitor cells.37,38 Moreover, adipocytes dif-
ferentiated from these progenitors affected glucose metab-
olism when implanted into immunocompromised mice.38
We now wish to further understand whether these cells (re-
ferred to as primed ADipocyte progenitor cells, PADS) are ca-
pable of forming structured, long-lived AT that could be used in
surgical applications. In this article, we use quantitative mor-
phometric and biochemical methods to investigate the process
by which PADS and adipocytes differentiated from PADS (ad-
PADS) form structured, functional AT in vivo, and compare it
to conventional AT grafting. We also compare the molecular
features of PADS and ad-PADS to those of ADSCs and ad-
ADSCs and report the results of comparative gene expression
analyses that identify unexpected pathways and genes asso-
ciated with the efficient formation of functional AT in vivo.
Results
In vivo, human adipocytes contain large lipid droplets,
display insulin responsive hypertrophy and leptin secretion,
and display long-term survival. To determine the similari-
ties between adipocytes formed from PADS (ad-PADS) and
functional human adipocytes, we quantified their growth over a
long time in culture in the absence or presence of insulin. Ex-
plants were cultured in Matrigel and EGM2-MV for 14 days,
and then switched to Dulbecco’s modified Eagle’s medium
(DMEM)+fetal bovine serum (FBS) containing an adipogenic
cocktail of methylisobutylxanthine, dexamethasone, and in-
sulin (MDI). After 3 days, cell cultures were continued in
DMEM+FBS, and images obtained at the times shown. We
find that ad-PADS survive many weeks in culture, during
which they transition from a multilocular to a unilocular phe-
notype (Fig. 1A) and progressively increase in size. After 14
weeks, cells are mostly unilocular, with abundant, functional
mitochondria as seen by staining with the mitochondrial dye
Mitotracker Red (Fig. 1B). Insulin promotes adipocyte hy-
pertrophy (Fig. 1C), and stimulates leptin secretion (Fig. 1D),
indicating that ad-PADS maintain the morphological and
functional properties of human adipocytes.
We then conducted experiments to determine whether ad-
PADS would form structured AT in vivo. Explants were
cultured in Matrigel for 14 days, and single cells obtained by
digestion with dispase. Cells were plated onto plastic culture
dishes and allowed to reach confluence before being ex-
posed to MDI for 3 days. After further culture for an addi-
tional 5 days, a time at which lipid droplets were beginning
to become visible, cells were collected using collagenase
and trypsin, washed and resuspended in Matrigel, and im-
planted subcutaneously into the flanks of nude mice. To
compare the process of tissue generation by ad-PADS to that
of mature AT grafting, a dry liposuction was performed on
an excised specimen containing skin and subcutaneous tis-
sue immediately following panniculectomy, and liposuction
fragments similarly implanted. Microcomputed tomography
(CT) scans taken after 8 weeks (Fig. 2A) revealed areas of
low attenuation at the sites of injection of AT fragments
(Fig. 2A, bottom panel), and smaller, higher attenuated areas
at the sites of injection of ad-PADS (Fig. 2A, top panel). To
measure graft functionality, we used a human-specific enzyme-
linked immunosorbent assay (ELISA) to measure circulat-
ing adiponectin, which reflects viability and vascularization
of grafted material. Human adiponectin was detectable in
most engrafted mice (Fig. 2B), but remarkably, the amount
of adiponectin per unit graft volume was 5–10 times higher
in ad-PADS compared to liposuction (Fig. 2C). To better
understand the differences in graft functionality, we per-
formed immunohistochemistry on the excised grafts. Visual
inspection (Fig. 2D) and quantitative image analysis
(Fig. 2E, Supplementary Fig. S1; Supplementary data are
available online at http://www.liebertpub.com/tea) of the
images revealed large decellularized regions in all grafts
formed from liposuction tissue, probably corresponding to
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lipid-filled cysts. These areas were undetectable in grafts
formed from ad-PADS (Fig. 2D). These results indicate that
ad-PADS are capable of further differentiation and growth
in vivo, and of efficient functional integration into the host.
To investigate the mechanisms by which PADS inte-
grate into the host, we analyzed the cellular composition of the
grafts using quantitative real time polymerase chain reaction
(qRT-PCR). We developed species-specific primers to the
adipocyte lipid dropletmarker perilipin 1 (mousePlin1, human
PLIN1), and to the mature endothelial cell marker vascular
endothelial-cadherin (mouse Cdh5, human CDH5). Grafts
formed from ad-PADS contained equal amount of human
PLIN1 compared to human subcutaneous AT (Fig. 3A), indi-
cating high enrichment of lipid-laden adipocytes. In contrast,
grafts formed from liposuction showed marked depletion of
PLIN1, reflecting loss of functional adipocytes (Fig. 3A). Both
types of grafts contained high levels of mouse Cdh5 (Fig. 3B),
reflecting vascularization from the host, but only grafts formed
from liposuction tissue contained human CDH5 (Fig. 3C), in-
dicating that ad-PADS do not differentiate into mature endo-
thelial cells under these conditions.24 Mouse Plin1 was very
low in both graft types, indicating negligible contamination
from the host AT (Fig. 3D). These results indicate that grafts
formed from ad-PADS are composed of human adipocytes
perfused by mouse vasculature.
The higher survival and functionality of ad-PADS com-
pared to liposuction in the cohort described above could
potentially be due by the large difference in volume between
the two types of grafts, or by the use of Matrigel during
grafting of ad-PADS. The larger volume of liposuction tissue
compared to ad-PADS may induce hypoxia (suggested by
high levels of CDH5), inflammation, and adipocyte death. In
addition, Matrigel has autonomous properties that facilitate
adipogenesis.39 To better compare the inherent properties of
ad-PADS and liposuction tissue, we performed experiments
using smaller volumes of liposuction tissue with the inclusion
of Matrigel. In parallel, we examined whether supplementa-
tion with ad-PADS would affect the engraftment of liposuc-
tion tissue. Three cohorts of mice were randomized to be
injected unilaterally subcutaneously with 500mL of materials
as follows: group A—liposuction tissue (250mL) in Matrigel
(250mL); group B—ad-PADS (100mL, *107 cells) in Ma-
trigel (400mL); and group C—liposuction tissue (225mL) and
ad-PADS (50mL, *5· 106 cells) in Matrigel (225mL).
Five days following implantation, micro-CT scans revealed
areas of low attenuation where liposuction fragments were
engrafted (Fig. 4, left top and bottom panels), but the regions
where ad-PADS were implanted were not distinguishable, due
to their low lipid content at the time of grafting (Fig. 4, left
middle panels) and the rapid reabsorption of Matrigel liquid
volume after implantation. After 11 and 16 weeks, grafts
formed from liposuction fragments had reduced in volume and
developed small regions of high attenuation consistent with
calcifications (Fig. 4A, right panels, asterisks). In contrast,
regions where ad-PADS were implanted were now less atten-
uated, consistent with further differentiation and lipid accu-
mulation of implanted cells, and no evidence of calcification
was seen. Atweek 16,micewere sacrificed and grafts collected
for further analysis. Grafts of liposuction fragments were
encapsulated and surrounded by small blood vessels, whereas
tissue formed from ad-PADS resembled normal AT (Fig. 4B).
Histochemical analysis revealed basophilic structures charac-
teristic of calcification, and large decellularized regions in
grafts of liposuction fragments. In contrast, a well-vascularized
FIG. 1. Development and properties of
PADS from human AT explants. (A) Re-
presentative image of an explant from hu-
man subcutaneous AT (top left corner of
each panel) in culture for the time indicated
above each panel. (B) Higher magnification
of specific section of well, taken at the times
indicated. At week 14, Mitotracker red was
added and cells imaged after 30min. (C)
Mean adipocyte size over time, from ex-
plants grown in the presence or absence of
additional insulin added to the culture me-
dium (100 nM). Symbols are the mean and
bars are SEM of adipocyte sizes, obtained
from five independent wells per time point
as described in Materials and Methods.
Statistical significance was estimated using
two-way ANOVA with Dunnett’s correc-
tion for multiple comparisons. *p < 0.05,
****p< 0.0001 versus week 7; ####p< 0.0001
versus no insulin. (D) Concentration of leptin
in media after 24 h of culture at week 14.
Shown are means and SEM of 8–10 wells.
Statistical significance was estimated using
two-tailed unpaired Mann–Whitney test.
***p< 0.001. ANOVA, analysis of variance;
AT, adipose tissue; PADS, primed
ADipose progenitor cells; SEM, standard
error of the mean.
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AT parenchyma distinguishable from the mouse dermal AT
was formed from ad-PADS (Fig. 4C).
Analysis of graft volume over time showed a decreasing
trend in grafts formed by liposuction fragments, but a sig-
nificant increase in grafts formed from ad-PADS (Fig. 5A).
Functionally, circulating adiponectin significantly increased
between weeks 11 and 16 in mice grafted with ad-PADS, but
not in mice grafted with liposuction tissue (Fig. 5B). More-
over, ad-PADS were much more efficiently integrated, pro-
ducing over 10·more adiponectin relative to graft volume
(Fig. 5C). These results are consistent with those seen in the
first cohort (Fig. 2). Both cohorts were analyzed using a
three-component agonist-versus-response fit (Fig 5D). This
analysis shows that, at similar graft volumes, ad-PADS pro-
duce larger amounts of adiponectin compared to liposuction
tissue. Therefore, the enhanced ability of ad-PADS compared
to liposuction to induce host vascularization and produce
adiponectin cannot be attributed to a smaller graft volume.
To further understand the determinants of graft growth
and functionality, we assessed the contributions of donor
and host vasculature in each graft type. Both qRT-PCR
(Fig. 5E–H) and whole-mount staining with human- and
mouse-specific lectins (Fig. 5I) were performed. Grafts
formed with liposuction tissue contained high levels of hu-
man CDH5 (Fig. 5G), and vascular staining was detected
with human-specific lectin (Fig. 5I), although at a lower
FIG. 2. Comparison of grafts formed from ad-PADS and from liposuction tissue. (A)Micro-CT scan of mice implanted with
PADS (23 weeks post-implantation, top panel) or liposuction tissue (7 weeks post-implantation, bottom panel). Areas of low
attenuation are enclosed by red dotted lines. (B) Levels of human adiponectin in plasma from mice implanted as in (A). Each
symbol represents the value for each mouse in the cohort. (C) Ratio of implant area versus circulating adiponectin. Each
symbol represents one mouse, and lines represent the mean and SEM. Statistical significance was estimated using a two-tailed
unpaired t-test with Welch’s correction for unequal standard deviations. *p< 0.05. (D) Histochemical staining of implants
formed from PADS (top panels) or liposuction tissue (bottom panels). Expanded regions illustrate the algorithm output for
selection of particles used for quantification. (E) Histogram of particle sizes obtained from the mean values of five independent
grafts from ad-PADS and seven independent grafts from liposuction tissue. Visual inspection was used to estimate adipocytes
as those particles with values lower than between 100 and 5000mm2. Statistical significance was estimated using the Friedman
test of frequency distributions as implemented in Prism 7.0. ****p< 0.0001. CT, computed tomography.
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density than that seen in control human AT. Staining with
mouse-specific lectin was also seen, but the staining was less
well organized than that seen in control mouse tissue or in
grafts formed from ad-PADS (Fig. 5I). These grafts also
expressed low levels of human PLIN1 (Fig. 5F), suggesting
low adipocyte viability. Grafts formed from ad-PADS
contained high levels of mouse Cdh5 (Fig. 5E), and mouse-
specific lectin revealed a well-developed vascular architec-
ture (Fig. 5I), and very high levels of human PLIN1. Grafts
formed from liposuction tissue supplemented with ad-PADS
contained higher levels of mouse Cdh5 messenger RNA
(mRNA) expression (Fig. 5E, compare Liposuction vs. Lipo+
adPADS), and stronger staining with mouse-specific lectin,
suggesting a significant proangiogenic effect of these cells.
To better understand the features of PADS, we compared
their properties to ADSCs derived from the SVF by stan-
dardized procedures as described in Figure 6A. We first
measured a panel of classical mesenchymal stem cell
markers by qRT-PCR. PADS expressed significantly higher
levels of some markers, including PDGFRa, which has been
associated with adipocyte progenitors in mouse models, and
lower levels of CD24 (Fig. 6B). These differences were
sustained after adipogenic differentiation and correlated
with increased levels of adipocyte markers (Fig. 6C) and
lipid accumulation (Fig. 6D) in ad-PADS. These results
indicate that PADS are more enriched in adipocyte pro-
genitors compared to ADSCs.
To compare the properties of ADSCs and PADS in vivo,
mice were engrafted with equal numbers of these cells.
Neither ADSCs nor PADS were able to form a func-
tional AT graft: excised ADSC graft remnants revealed the
presence of numerous cell nuclei, but no lipid droplet ac-
cumulation (Fig. 6E), while remnants from PADS grafts
displayed few lipid droplets. Interestingly, vessel-like struc-
tures staining with human-specific lectin (Fig. 6E, arrows),
and significantly higher levels of human CDH5 (Fig. 6F)
could be detected in ADSC graft remnants, but not in rem-
nants from PADS, suggesting that ADSCs are capable of
forming microvessels in vivo. These results above indicate
that induction of adipogenic differentiation in vitro is abso-
lutely required for PADS to generate functional AT in vivo.
To explore the molecular differences between PADS and
ad-PADS that could contribute to tissue formation, we con-
ducted HTA-2 Affymetrix whole genome arrays. Of >33,000
mRNAs detected, 269 coding genes were differentially ex-
pressed between pre-PADS and PADS (Fig. 6G; Supple-
mentary Table S1). Of these, 40 genes containing the gene
ontology cellular component term ‘‘extracellular’’ (including
‘‘exosomal’’) were upregulated in response to differentiation
(Fig. 6H; Table 1). The top biological processes identified
through enrichment analysis of this set were ‘‘response to
oxygen’’ and ‘‘response to wounding’’ (Table 2), and in-
cluded four collagen species (COL4A1, COL5A1, COL3A1,
and COL12A1), adhesion proteins (MCAM/CD146, CHL1,
and HSPG2), extracellular matrix remodeling proteins
(ADAMTS9, OLFM2, and SERPINB2), and secretory hy-
drolases (PLA2G2A and CH3L2). Also in this list were the
expected adipokines and adipocyte-secreted proteins ADI-
POQ, FABP4, LPL, FABP5, and RBP4. Interestingly, none
of these genes corresponded to known classical proangio-
genic growth factors, suggesting that the mechanisms by
which PADS are capable of forming functional AT in vivo is
through the generation of an extracellular matrix niche op-
timal for adipogenic differentiation and host vascularization.
Discussion
Toour knowledge, this article is first to describe amethod by
which functional, structured human AT can be formed in vivo
from progenitor cells. The finding that ADSCs can be obtained
from human AT has been a critical advancement in regenera-
tive medicine. However, the number of cells that can be ob-
tained is limited; standard methods to obtain ADSCs involve
collagenase digestion to obtain the SVF and selection of
mesenchymal progenitors through their capacity to attach to
plastic surfaces. This can lead to damage from protease action
and low yields due to low plating efficiency. A remarkable
feature of PADS is that large number of cells can be obtained
from small amounts of human AT. Specifically, the number of
ADSCs obtained from liposuction tissue varies widely, from
FIG. 3. Human or mouse adipocyte and endothelial cell
content in grafts formed from ad-PADS and from liposuc-
tion tissue. RNA from excised grafts was analyzed using
species-specific RT-PCR probes for the genes indicated
above each panel. Symbols represent values for three tissue
samples and six to seven grafts per condition assayed in
triplicate, and the mean and SEM of all grafts are shown.
Statistical significance was estimated using multiple t-tests
corrected for multiple comparisons using the Holm-Sidak
method. Black circle indicates mouse adipose tissue; white
circle indicates human adipose tissue; red circle indicates ad-
PADS; yellow circle indicates liposuction fragments.
*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.00001.
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5· 105 to 2· 106 cells per gram of AT, with 1 to 10% of these
considered to be ADSCs.15,40 ADSCs expanded in culture
cease to replicate after 15populationdoublings41 and display in
increasing senescence markers after 4 doublings.27 Thus, the
maximal yield ofADSCs from1g ofAT can be estimated to be
a maximum of 6· 106 after five passages. In contrast, explants
from 0.25 cm3 (*200mg) of AT yielded 2· 107 cells after
14 days in culture and 8· 107 adherent cells 72 h after plating in
plastic. In our hands, PADS are passaged in a 1:2 split after this
step to yield 1.7· 108 cells, which are frozen and can be ex-
panded through five population doublings with no decrease in
adipose differentiation capacity. Therefore *5· 109 PADS
can be obtained from 1g of human AT, representing a
1000· higher yield than ADSCs. It is possible that three-
dimensional (3D) organ culture triggers a physiological in-
duction of progenitor cell proliferation, which in combination
with minimal damage from mechanical or chemical stress
leads to very high yields of mesenchymal progenitor cells.
The differences between ADSCs and PADS extend beyond
the yield of cells obtained through different techniques, as cell
surface marker content differs significantly (Fig. 6B, C) as do
functional outcomes. It is interesting that ADSCs seem more
capable of producing vascular structures in vivo (Fig. 6E, F),
consistent with numerous reports of their proangiogenic ef-
fects.42–47 In contrast, PADS are more able to differentiate into
adipocytes, and can induce host angiogenesis. These functional
differences are likely due to the different complement of cells
making up the ADSC and PADS populations.
An important finding in this study is that the ability to form
structured AT in vivo is highly dependent on prior induction
of adipogenic differentiation in vitro. Comparison of PADS
and ad-PADS can thus inform on the biochemical pathways
important for tissue generation. As expected, the most sig-
nificant biological pathways enriched in ad-PADS compared
to PADS are related to canonical AT function, with the top 20
corresponding to lipid metabolic processes, including storage
and catabolism. However, the first non-lipid related pathway
significantly enriched is that of wound healing (Supplemen-
tary Table S2). When the differentially expressed genes are
restricted to those associated with the extracellular compart-
ment, the second most enriched pathway corresponds to
wound healing (Table 2). Strikingly, none of the genes pre-
viously associated with angiogenesis in the context of
ADSCs, which include VEGF FGF-2, HGF, and TGF-b,48
was found. Rather, extracellular matrix components, includ-
ing five different collagen types, were the predominant as-
sociated genes. One of these, COL4A1, is essential for small
vessel development and pathogenic mutations cause vascular
FIG. 4. Development of grafts from ad-
PADS and liposuction tissue using compa-
rable volumes. (A) Micro-CT scans of mice
implanted with liposuction tissue (top pan-
els), ad-PADS (middle panels), and lipo-
suction tissue supplemented with ad-PADS
(bottom panels) at the times following
grafting indicated on top. Areas of low
attenuation are outlined with red dotted
traces, and examples of high attenuation
objects within these areas, possibly corre-
sponding to calcifications, are indicated with
asterisks. (B) Macroscopic appearance of
grafts at sacrifice. (C) Histochemical stain-
ing of grafts. Grafted tissue under the skin is
outlined with black, segmented traces, and
basophilic objects within decellularized re-
gions are illustrated with asterisks in the
expanded images. Examples are representa-
tive of seven grafts per condition.
HUMAN ADIPOSE TISSUE GENERATED IN VIVO 847
F
IG
.
5
.
Q
u
an
ti
fi
ca
ti
o
n
o
f
g
ra
ft
v
o
lu
m
e,
fu
n
ct
io
n
al
it
y
,
an
d
en
d
o
th
el
ia
l
o
r
ad
ip
o
se
ce
ll
co
n
te
n
t.
(A
)
M
ea
n
an
d
S
E
M
o
f
g
ra
ft
v
o
lu
m
es
ca
lc
u
la
te
d
fr
o
m
m
ic
ro
-C
T
sc
an
s,
an
d
(B
)
m
ea
n
an
d
S
E
M
o
f
h
u
m
an
ad
ip
o
n
ec
ti
n
in
p
la
sm
a,
o
b
ta
in
ed
at
th
e
ti
m
es
sh
o
w
n
o
n
th
e
x-
ax
es
,
fr
o
m
se
v
en
m
ic
e
p
er
co
n
d
it
io
n
im
p
la
n
te
d
w
it
h
li
p
o
su
ct
io
n
ti
ss
u
e,
ad
-P
A
D
S
,
o
r
li
p
o
su
ct
io
n
ti
ss
u
e
su
p
p
le
m
en
te
d
b
y
ad
-P
A
D
S
.
S
ta
ti
st
ic
al
si
g
n
ifi
ca
n
ce
w
as
es
ti
m
at
ed
u
si
n
g
p
ai
re
d
t-
te
st
s.
*
p
<
0
.0
5
,
*
*
p
<
0
.0
1
.
(C
)
M
ea
n
an
d
S
E
M
o
f
th
e
ra
ti
o
s
o
f
h
u
m
an
ad
ip
o
n
ec
ti
n
to
g
ra
ft
v
o
lu
m
es
at
1
6
w
ee
k
s
p
o
st
g
ra
ft
in
g
in
m
ic
e
h
ar
b
o
ri
n
g
g
ra
ft
s
fr
o
m
li
p
o
su
ct
io
n
ti
ss
u
e,
ad
-P
A
D
S
,
o
r
li
p
o
su
ct
io
n
ti
ss
u
e
su
p
p
le
m
en
te
d
b
y
ad
-P
A
D
S
.
S
ta
ti
st
ic
al
si
g
n
ifi
ca
n
ce
w
as
es
ti
m
at
ed
u
si
n
g
o
n
e-
w
ay
A
N
O
V
A
w
it
h
T
u
k
ey
’s
co
rr
ec
ti
o
n
fo
r
m
u
lt
ip
le
co
m
p
ar
is
o
n
s,
*
*
p
<
0
.0
1
.
(D
)
R
el
at
io
n
sh
ip
b
et
w
ee
n
g
ra
ft
v
o
lu
m
e
an
d
p
la
sm
a
ad
ip
o
n
ec
ti
n
in
m
ic
e
fr
o
m
co
h
o
rt
s
1
(s
q
u
a
re
s)
an
d
2
(c
ir
cl
es
).
E
ac
h
sy
m
b
o
l
co
rr
es
p
o
n
d
s
to
v
al
u
es
fr
o
m
o
n
e
m
o
u
se
.
(E
–
H
)
R
N
A
fr
o
m
ex
ci
se
d
g
ra
ft
s
w
as
an
al
y
ze
d
u
si
n
g
sp
ec
ie
s-
sp
ec
ifi
c
q
R
T
-P
C
R
p
ro
b
es
fo
r
th
e
g
en
es
in
d
ic
at
ed
ab
o
v
e
ea
ch
p
an
el
.
B
ar
s
re
p
re
se
n
t
th
e
m
ea
n
an
d
li
n
es
th
e
S
E
M
o
f
al
l
g
ra
ft
s.
S
ta
ti
st
ic
al
si
g
n
ifi
ca
n
ce
w
as
es
ti
m
at
ed
u
si
n
g
th
e
K
ru
st
al
–
W
al
li
s
te
st
w
it
h
D
u
n
n
et
t’
s
co
rr
ec
ti
o
n
fo
r
m
u
lt
ip
le
co
m
p
ar
is
o
n
s.
*
*
p
<
0
.0
1
,
*
*
*
p
<
0
.0
0
1
,
*
*
*
*
p
<
0
.0
0
0
0
1
.
(I
)
W
h
o
le
-m
o
u
n
t
st
ai
n
in
g
o
f
fr
ag
m
en
ts
fr
o
m
co
n
tr
o
l
h
u
m
an
an
d
m
o
u
se
A
T
,
an
d
fr
o
m
g
ra
ft
s
fo
rm
ed
fr
o
m
li
p
o
su
ct
io
n
ti
ss
u
e,
ad
-P
A
D
S
,
o
r
li
p
o
su
ct
io
n
ti
ss
u
e
su
p
p
le
m
en
te
d
b
y
ad
-P
A
D
S
,
co
st
ai
n
ed
w
it
h
m
o
u
se
-
an
d
h
u
m
an
-s
p
ec
ifi
c
le
ct
in
s
an
d
D
A
P
I.
D
A
P
I,
4
¢,6
-d
ia
m
id
in
o
-2
-p
h
en
y
li
n
d
o
le
(n
u
cl
ea
r
st
ai
n
in
g
);
m
R
N
A
,
m
es
se
n
g
er
R
N
A
;
q
R
T
-P
C
R
,
q
u
an
ti
ta
ti
v
e
re
al
ti
m
e
p
o
ly
m
er
as
e
ch
ai
n
re
ac
ti
o
n
.
848
FIG. 6. Molecular features associated with tissue formation. (A) Schematic representing the methods to obtain PADS, ad-
PADS, ADSCs, and ad-ADSCs. (B, C) RNA from two independent preparations of PADS, ad-PADS, ADSCs, and ad-
ADSCs was probed for the mesenchymal stem cell (B, C) and adipocyte (C) markers depicted on the x-axis. Values are
expressed as the fold over the lowest value for each probe set. Statistical significance was estimated using multiple t-tests
corrected for multiple comparisons using the Holm-Sidak method. Double headed arrows are placed over sets of probes that
differed significantly, at the levels indicated **p< 0.01, ***p < 0.001, ****p < 0.00001. (D) Oil Red O staining of ad-
ADSCs and ad-PADS after 10 days of differentiation. (E) Whole-mount costaining of grafts formed from ADSCs and
PADS using DAPI, and mouse- and human-specific lectins. Control human and mouse AT are included for comparison.
Linear structures stained with human-specific lectin in grafts formed from ADSCs are indicated with red arrows. (F) RNA
from excised grafts was analyzed using species-specific qRT-PCR probes for the genes indicated on the x-axis. Bars
represent the mean, and lines the SEM of seven grafts per condition assayed in duplicate. Statistical significance was
estimated using the Krustal–Wallis test with Dunnett’s correction for multiple comparisons. **p< 0.01. (G) Heat map of
differentially expressed genes between PADS and ad-PADS, obtained from AT from five different individuals. (H) Heat
map of differentially expressed genes containing the GO term ‘‘extracellular.’’ ADSCs, ADipose stem cells.
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abnormalities,49–52 suggesting it may have an important role
in vascularization of PADS for engraftment. Also, mutations
in COL3A1 give rise to vascular Ehlers–Danlos syndrome,53
indicating a role for this collagen type in vascular integrity.
Other identified genes includeMCAM/CD146,which has been
implicated in lymphangiogenesis,54 brain endothelial cell
functions,55 and angiogenesis.56,57 The interactions among
these genes may also be critically important for tissue devel-
opment, as has been reported for themorphogenesis of vascular
structures through interactions between ADAMTS9 with
Table 1. Genes Containing the Gene Ontology:Cell Component Term ‘‘Extracellular’’
That are Upregulated in ad-Primed ADipose Progenitor Cells (PADS) Compared to PADS
Gene
symbol
Biweight Average signal (Log2)
pre-PADS PADS
Fold
change
(linear)
ANOVA
p-value
FDR
p-value Description
COL12A1 15.62 16.63 2.02 0.034278 0.738561 Collagen, type XII, alpha 1
COL3A1 14.76 15.83 2.1 0.014497 0.706983 Collagen, type III, alpha 1
ADIPOQ 6.02 14.15 278.53 0.001938 0.63372 Adiponectin
PPP2R1B 9.85 12.13 4.83 0.012173 0.706983 Protein phosphatase 2, regulatory
subunit A, beta
ERV3-1 9.04 11.89 7.22 0.001606 0.63372 Endogenous retrovirus group 3, member 1;
zinc finger protein 117
HSPG2 10.6 11.75 2.22 0.011174 0.702326 Heparan sulfate proteoglycan 2
ACACA 8.75 11.6 7.2 0.035299 0.738561 Acetyl-CoA carboxylase alpha
CAT 9.87 11.22 2.56 0.01749 0.717727 Catalase
LPL 4.61 11.06 87.66 0.008961 0.697682 Lipoprotein lipase
ECHDC1 9.19 11.01 3.52 0.030393 0.730714 Ethylmalonyl-CoA decarboxylase 1
HP 5 10.98 63.29 0.007908 0.694757 Haptoglobin
C7 7.59 10.97 10.39 0.023862 0.725644 Complement component 7
RBP4 7.18 10.59 10.6 0.019018 0.720701 Retinol binding protein 4, plasma
FZD4 8.85 10.56 3.27 0.035148 0.738561 Frizzled class receptor 4
OLFM2 8.37 10.53 4.47 0.003836 0.640504 Olfactomedin 2
COL4A1 8.43 10.19 3.37 0.049268 0.765581 Collagen, type IV, alpha 1
PLA2G2A 7.93 10.06 4.38 0.011995 0.70568 Phospholipase A2, group IIA
(platelets, synovial fluid)
CHI3L2 6.32 9.95 12.39 0.000282 0.453651 Chitinase 3-like 2
MCAM 5.94 9.87 15.28 0.012533 0.706983 Melanoma cell adhesion molecule
GHR 6.74 9.76 8.12 0.014529 0.706983 Growth hormone receptor
LBP 5.63 9.7 16.82 0.011861 0.70411 Lipopolysaccharide binding protein
GPD1 5.6 9.42 14.16 0.009315 0.69817 Glycerol-3-phosphate dehydrogenase 1
PRKAR2B 6.2 9.41 9.23 0.007145 0.68923 Protein kinase, cAMP-dependent,
regulatory, type II, beta
CHL1 7.79 9.02 2.35 0.042315 0.752979 Cell adhesion molecule L1 like
COL5A1 7.58 8.62 2.06 0.045381 0.756446 Collagen, type V, alpha 1
FABP5 5.73 8.46 6.6 0.011525 0.702953 Fatty acid binding protein 5 (psoriasis associated)
ADIRF 6.54 8.29 3.36 0.020917 0.724127 Adipogenesis regulatory factor
EFNA5 6.89 8.14 2.37 0.016816 0.717167 Ephrin-A5
PRL 5.67 7.91 4.72 0.001102 0.625574 Prolactin
APOE 6.45 7.71 2.4 0.038401 0.742836 Apolipoprotein E
ITIH5 6.35 7.67 2.51 0.005753 0.666918 Inter-alpha-trypsin inhibitor heavy
chain family, member 5
HPR 5.36 7.32 3.9 0.012947 0.706983 Haptoglobin-related protein; haptoglobin
SERPINB2 5.66 7.13 2.78 0.043889 0.752979 Serpin peptidase inhibitor,
clade B (ovalbumin), member 2
MAOB 5.48 6.65 2.24 0.0157 0.711636 Monoamine oxidase B
ADAMTS9 4.89 6.57 3.23 0.003176 0.63372 ADAM metallopeptidase with
thrombospondin type 1 motif 9
TRHDE 4.77 6.51 3.36 0.014351 0.706983 Thyrotropin-releasing hormone-
degrading enzyme
CKMT1B 5.17 6.22 2.07 0.042988 0.752979 Creatine kinase, mitochondrial 1B;
creatine kinase, mitochondrial 1A
PPP1R1A 5.19 6.21 2.03 0.015221 0.711636 Protein phosphatase 1, regulatory
(inhibitor) subunit 1A
CKMT1A 4.42 5.53 2.15 0.049139 0.765232 Creatine kinase, mitochondrial 1A;
creatine kinase, mitochondrial 1B
The signals are means from five independent arrays, and values are sorted based on intensity of signal in ad-PADS.
ANOVA, analysis of variance; FDR, false discovery rate; PADS, primed ADipose progenitor cells.
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HSPG2.58,59 How these genes exert these specific actions is not
known, but the use of ad-PADS grafting as a model may be
useful for elucidating their molecular functions.
The therapeutic use of ad-PADS is an exciting prospect in
reconstructive surgery, particularly in instances such as
wound healing or restoration of soft tissue volume after
cancer surgery. Ad-PADS could be used alone for small
reconstructive requirements or in combination with lipo-
suction tissue to enhance large volume grafting. In our
study, supplementation of liposuction tissue with PADS
significantly enhanced vascularization, and further experi-
ments will determine whether an optimal ratio of ad-PADS
to tissue can achieve functionally improved grafting. The
therapeutic use of PADS could extend beyond reconstructive
surgery. For example, in congenital generalized lipodystro-
phies, there is a virtual absence of adiponectin and leptin due
to genetic defects preventing adipose differentiation. PADS
from these subjects could be corrected in vitro, and autolo-
gous implantation of in vitro-generated ad-PADS could po-
tentially ameliorate endocrine pathology in these cases.
The limitations of this work are that, like ADSCs, PADS
are heterogeneous, and we cannot fully describe their
complexity or identify the specific complement of cells re-
quired for AT formation in vivo. This next step will require
the development of methods to identify and enrich the
different progenitor subpopulations, and to examine their
ability to engraft singly or in combinations. Nevertheless,
the capacity of PADS to form functional AT has been re-
produced in our laboratory with a minimum of 5 different
cell preparations from different donors, using both NSG38
and nude mouse strains (current results), indicating robust
conserved mechanisms at play. An additional limitation is
the use of Matrigel for 3D expansion of PADS. Identifica-
tion of good manufacturing practice-compliant hydrogels
that can replace Matrigel is a necessary step in using ad-
PADS to improve therapeutic outcomes.
In summary, this article demonstrates that ad-PADS can
form structured AT in vivo by inducing strong vascularization
from the host and continued human adipocyte growth and dif-
ferentiation. Enrichment of liposuction with ad-PADS im-
proves vascularization, indicating that ad-PADS may be
proangiogenic, possibly through expression of extracellular
matrix elements previously associated with small vessel de-
velopment. The capacity to generate very large numbers of
PADS from small amounts of AT increases their potential to
improve outcomes in reconstructive and regenerativemedicine.
Materials and Methods
Specific reagents
Matrigel (BD Biosciences); EGM-2 MV (Lonza); Adi-
ponectin human-specific ELISA (Invitrogen KHP0041);
Table 2. Biological Processes Showing Enrichment of Genes Containing the Gene Ontology:Cell
Component Term ‘‘Extracellular’’ That are Upregulated in ad-Primed ADipose
Progenitor Cells (PADS) Compared to PADS
GO biological
process ID Name p-value
q-value
Bonferroni
Hit count in
query list
Hit count
in genome Hit in query list
GO:1901700 Response to
oxygen-containing
compound
6.49E-09 1.23E-05 17 1614 COL3A1, FZD4, COL4A1,
GHR, GPD1, PRKAR2B,
CAT, LBP, ADIPOQ,
EFNA5, APOE, ACACA,
MAOB, HP, PRL,
LPL, RBP4
GO:0009611 Response to wounding 4.24E-08 8.06E-05 13 967 CHL1, COL3A1, MCAM,
PLA2G2A, PRKAR2B,
COL5A1, LBP, ADIPOQ,
C7, APOE, LPL, FABP5,
SERPINB2
GO:0044236 Multicellular organism Metabolic
process
5.09E-07 9.68E-04 6144 COL3A1, COL4A1, GHR,
COL5A1, COL12A1,
ACACA
GO:0044255 Cellular lipid
metabolic process
1.06E-06 2.01E-03 12 1064 GHR, GPD1, PLA2G2A,
PRKAR2B, HSPG2, CAT,
ADIPOQ, APOE, ACACA,
LPL, FABP5, RBP4
GO:0006600 Creatine metabolic 1.39E-06 2.63E-03 3 11 GHR, CKMT1B, CKMT1A
GO:0006641 Triglyceride metabolic
process
4.01E-06 7.62E-03 5 115 GPD1, CAT, APOE,
LPL, FABP5
GO:1901701 Cellular response to
oxygen-containing
compound
4.27E-06 8.12E-03 11 1001 COL3A1, FZD4, COL4A1,
GHR, GPD1, PRKAR2B,
LBP, ADIPOQ, EFNA5,
ACACA, PRL
GO:0044259 Multicellular
organismal
macromolecule
6.52E-06 1.24E-02 5 127 COL3A1, COL4A1, COL5A1,
COL12A1, ACACA
GO:0006639 Acylglycerol
metabolic process
6.77E-06 1.29E-02 5 128 GPD1, CAT, APOE,
LPL, FABP5
GO, gene ontology.
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Rhodamine Ulex europaeus Agglutinin 1 (Vector labs RL-
1062); and Isolectin GS IB4 Alexa Fluor 488 Conjugate
(Life Technologies I21411).
Adipose tissue
Subcutaneous AT for grafting and for derivation of PADS
was obtained from panniculectomies with no a priori se-
lection of individual donors. All specimens were collected
in accordance with procedures approved by the University
of Massachusetts Institutional Review Board (IRB).
Liposuction tissue
Tissue was obtained from panniculectomies performed at
our institution, under an approved IRB. Immediately after
excision of the panniculus from the patient, AT was ex-
tracted manually in multiple passes with a 3mm cannula,
and centrifuged at 3000 RPM for 3min. Aqueous and lipid
components were discarded and fat used for grafting di-
rectly, or after mixing with an equal volume of Matrigel by
gentle inversion, as indicated in each experiment. In some
experiments, the 50/50 mixture of liposuction tissue and
Matrigel was supplemented with PADS as described in the
Results section.
Cells
Detailed methods for harvesting AT, culture of AT ex-
plants in Matrigel, and harvesting of single cells from ex-
plant growth are published.60 In brief, explants from human
subcutaneous AT were cultured in EBM-2 media supple-
mented with endothelial growth factors (EGM-2 MV)
(Lonza) for 14 days. Single-cell suspensions from capillary
growth were obtained using dispase (yield *2 · 107 cells
from one 10 cm plate) and plated into two 15 cm tis-
sue culture dish. After 72 h, cells were split 1:2, grown
for an additional 72 h, recovered by trypsinization (yield
*8 · 107), and frozen into 10 vials. To generate PADS for
grafting, single vials were thawed out and plated into
1 · 150mm dish per graft and grown to confluence in EGM-
2 MV. Differentiation was induced by replacement of
EGM-2 MV by DMEM +10% FBS, 0.5mM 3-isobutyl-1-
methylxanthine, 1 mM dexamethasone, and 1 mg/mL insulin
(MDI). Seventy-two hours later, the differentiation medium
was replaced by DMEM-FBS, which was replaced every
48 h for 10 days.
Mice
All animal use was in accordance with the guidelines of
the Animal Care and Use Committee of the University of
Massachusetts Medical School. Male nude mice were ob-
tained from the Charles River Laboratories. Liposuction
tissue, PADS, or a combination as indicated were grafted
subcutaneously into the flank 5 cm cephalad to the tail and
3 cm lateral to the spine. Under sterile conditions, an 18G IV
cannula was used to penetrate the skin at the base of the tail
of each mouse. The needle was withdrawn and the shield
of the catheter was advanced to the selected area, creating
a tunnel by blunt dissection. A semirigid circular-shaped
plastic splint with a central hole of 1.5 cm diameter was
positioned on the skin encircling the selected area to be
grafted, to ensure proper location and prevent displacement
of the graft at the time of injection. The splint was left in
place for 3 days and then removed. Serial volumetric anal-
ysis by micro-CT scanning was performed as described.61
Immediately after euthanasia, grafts were dissected, and half
of the graft was fixed in 4% paraformaldehyde for micros-
copy and half used for RNA extraction using TRIzol. For
RT-PCR, total RNA was reverse transcribed using the iS-
cript cDNA Synthesis Kit (Bio-Rad). cDNA was used as
template for qRT-PCR using the iQ SYBR Green Supermix
Kit (Bio-Rad) and the CFX96 Real-Time System (Bio-Rad).
Human ribosomal protein L4 (RPL4) was used for nor-
malization.
Gene expression
For RT-PCR, total RNA was reverse transcribed using the
iScript cDNA Synthesis Kit (Bio-Rad). cDNA was used as
template for qRT-PCR using the iQ SYBR Green Supermix
Kit (Bio-Rad) and the CFX96 Real-Time System (Bio-Rad).
RPL4 was used for normalization. Human- and mouse-
specific probe sets are shown in Supplementary Table S3.
For Affymetrix arrays, total RNA was isolated using TRIzol,
from pre-PADS and PADS obtained from five independent
subjects. Affymetrix protocols were followed for the prep-
aration of cRNA, which was hybridized to HTA-2.0 ar-
rays. Raw expression data collected from an Affymetrix HP
GeneArrayScanner were normalized across all data sets
using the robust multi-array algorithm as implemented by
the Affymetrix Expression Console. Differential expression
analysis was performed using the Affymetrix Transcriptome
Analysis Console v.3.0. Pathway analysis of transcriptomic
data was performed using ToppGene.62
Histochemistry and quantification
Samples were fixed in 4% formaldehyde and embedded in
paraffin. Tissue sections (8-mm), were mounted on Super-
frost Plus microscope slides (Fisher Scientific) and stained
with hematoxylin and eosin; 10 · images were taken using
brightfield microscopy (Zeiss Axiovert 35) and AxioCam
Icc 1 digital camera (Zeiss). Adipocyte (area) size was de-
termined using an automated procedure based on the open
software platform FIJI.63 In brief, images were imported,
local contrast enhanced (CLAHE, blocksize = 263, histo-
gram = 256, maximum = 40), converted to 8-bit grayscale
image, binarized (threshold 136, 255, dark background),
eroded (iterations = 1, count = 6, black, pad do=Erode), and
object number and size were measured (Analyze Particles,
size = 100-Infinity circularity = 0.10–1.00). Frequency dis-
tributions were obtained for each section using a bin size of
1000, and the mean and standard error of the mean for each
bin were calculated to generate the composite histogram for
each graft type. For whole-mount staining, tissue fragments
were fixed in 4% formaldehyde, washed, and stained with a
mixture of 50 mg/mL each Rhodamine Ulex europaeus Ag-
glutinin 1 (Vector labs RL-1062) and Isolectin GS IB4
Alexa Fluor 488 Conjugate (Life Technologies I21411) for
1 h at room temperature. After washing in phosphate-
buffered saline, fragments were mounted between 1.5mm
coverslips sealed with ProLong Gold Antifade Reagent
(Life Technologies).
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Statistical analysis
GraphPad Prism 7.0 was used for all analyses. Parametric
or nonparametric test were chosen based on results from
the D’Agostino-Pearson omnibus normality test, and are de-
scribed in each figure.
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